StockData
MeiraGTx Holdings plc logo

MeiraGTx Holdings plc (MGTX) company profile

MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/3065% below fair value
$8.46−0.28 (-3.20%)

Close on Nov 17, 2026Market cap $812.52MP/E 11.9Yield –

About MeiraGTx

Biological Products, (No Diagnostic Substances), SIC 2836

MeiraGTx is a vertically integrated, clinical-stage genetic medicines company focused on developing locally delivered genetic therapies for serious inherited and common disorders. Its clinical pipeline targets conditions including radiation-induced xerostomia, Parkinson’s disease, and inherited retinal dystrophies. The company designs and produces gene therapy candidates using internal end-to-end good manufacturing practices capabilities, encompassing viral vector production, plasmid DNA manufacturing, and quality control. In addition to therapeutic candidates, the enterprise develops proprietary technologies such as an oral small molecule-controlled synthetic riboswitch gene regulation platform, specialized delivery devices for central nervous system administration, and a T-cell progenitor cell therapy platform. Its pipeline activities serve patients through clinical research and strategic development collaborations with global pharmaceutical partners.

The company conducts operations across the United Kingdom, Ireland, and the United States, alongside research activities in France. Its manufacturing and testing infrastructure includes a 29,000-square-foot viral vector facility in London, United Kingdom, and a 150,000-square-foot campus in Shannon, Ireland, which houses commercial-scale viral vector and plasmid DNA production. The provided text does not state the company's corporate headquarters location.

Summary of the business section of MeiraGTx's latest annual report, written by StockData.

Company profile

Company

Legal name
MeiraGTx Holdings plc
Headquarters
New York, NY
Address
655 Third Avenue, Suite 1115 10017
Phone
(646) 860-7985
Employees
403, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Jericho, New York

Stock & identifiers

Ticker
MGTX
Exchange
Nasdaq
IPO date
Jun 8, 2018
Shares outstanding
96M, Aug 11, 2026
Public float
$524.51M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1735438
CUSIP
G59665102
FIGI
BBG00KXH44F2
Share class FIGI
BBG00KXH4D62
LEI
54930007YV6NYIOGFZ57
EIN
98-1448305

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Alexandria ForbesPRESIDENT & CEO, Director1,268,580
Richard GirouxCFO & COO942,682
Stuart NaylorCHIEF SCI OFCR, OPHTHALMOLOGY613,187
Robert K. ZeldinCHIEF MEDICAL OFFICER146,204
Robert J. WollinGENERAL COUNSEL AND SECRETARY63,326
Penny Renee FleckCHIEF DEVELOPMENT OFFICER–
Alan SebulskyDirector34,500
Nicole SeligmanDirector5,000
Debra YuDirector–
Ellen HukkelhovenDirector0
Life Sciences Master Fund Ltd PerceptiveDirector10,786,658
Joseph EdelmanDirector12,531,103
Thomas E. ShenkDirector157,476
Advisors Llc PerceptiveDirector6,933,277
Keith R. HarrisDirector200,000
Neil MendozaDirector12,883

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$8.33M$11.82M$4.88M$121–
FY2024$6.88M$6.05M$4.36M$93–
FY2023$6.34M$5.84M$3.74M$108–
FY2022$7.72M-$1.12M$5.29M$27–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOtherTotalvs. prior year
Alexandria Forbes, Ph.D.
President and Chief Executive Officer
$840.00K$1.65M$5.82M$21.00K$8.33M+21%
Richard Giroux
Chief Financial Officer and Chief Operating Officer
$714.00K$1.59M$5.82M$21.00K$8.15M+22%
Robert K. Zeldin, M.D.
Chief Medical Officer
$543.42K$500.00K$551.70K$21.00K$1.62M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 8, 2018
Offer price
$15.00
Securities offered
5,000,000
Gross proceeds
$75.00M
Exchange
Nasdaq
First trading day
Jun 8, 2018
First-day close
$15.000.0%
Lock-up ends (est.)
Dec 5, 2018

“Per Share Total Public offering price $15.00 $75,000,000 Underwriting discount(1) $ 1.05 $ 5,250,000 Proceeds, before expenses, to us $13.95 $69,750,000 (1) We refer you to “Underwriting” beginning on page 211 for additional information regarding underwriting compensation.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 403 employees, 400 of which are full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?